Three‐in‐One Oncolytic Adenovirus System Initiates a Synergetic Photodynamic Immunotherapy in Immune‐Suppressive Cholangiocarcinoma
Small · 2023
DOI: 10.1002/smll.202207668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Jialun Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Although photodynamic immunotherapy has been promoted in the clinical practice of cholangiocarcinoma, the insensitivity to photodynamic immunotherapy remains to be a great problem. This can be largely attributed to an immune‐suppressive tumor microenvironment (TME) manifested as immature myeloid cells and exhausted cytotoxic T lymphocytes. Here, a three‐in‐one oncolytic adenovirus system PEG‐PEI‐Adv‐Catalase‐KillerRed (p‐Adv‐CAT‐KR) has been constructed to multiply, initiate, and enhance immune responses in photodynamic immunotherapy, using genetically‐engineered KillerRed as photosensitizer, catalase as in situ oxygen‐supplying mediator, and adenovirus as immunostimulatory bio‐reproducible carrier. Meanwhile, PEG‐PEI is applied to protect adenovirus from circulating immune attack. The administration of p‐Adv‐CAT‐KR induces increased antigen presenting cells, elevated T cell infiltrations, and reduced tumor burden. Further investigation into underlying mechanism indicates that hypoxia inducible factor 1 subunit alpha (Hif‐1α) and its downstream PD‐1/PD‐L1 pathway contribute to the transformation of immune‐suppressive TME in cholangiocarcinoma. Collectively, the combination of KillerRed, catalase, and adenovirus brings about multi‐amplified antitumor photo‐immunity and has the potential to be an effective immunotherapeutic strategy for cholangiocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
- Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
- Nanjing Medical Center for Clinical Pharmacy, Nanjing, 210008, China.
- Department of Pain, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
ORCID-Profile: Xihan Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Zhu, Y., Chen, Y., Huang, Y., Guo, Q., Wang, Y., Chen, A., Zhou, Y., Xu, L., Wang, L., Zou, X., & Li, X. (2023). Three‐in‐One Oncolytic Adenovirus System Initiates a Synergetic Photodynamic Immunotherapy in Immune‐Suppressive Cholangiocarcinoma. Small. https://doi.org/10.1002/smll.202207668
Vancouver
Wang J, Zhu Y, Chen Y, Huang Y, Guo Q, Wang Y, et al. Three‐in‐One Oncolytic Adenovirus System Initiates a Synergetic Photodynamic Immunotherapy in Immune‐Suppressive Cholangiocarcinoma. Small. 2023. doi:10.1002/smll.202207668
BibTeX
@article{Wang2023,
author = {Wang, Jialun and Zhu, Yun and Chen, Yu and Huang, Ying and Guo, Qiyuan and Wang, Yue and Chen, Aotian and Zhou, Yue and Xu, Lei and Wang, Lei and Zou, Xiaoping and Li, Xihan},
title = {Three‐in‐One Oncolytic Adenovirus System Initiates a Synergetic Photodynamic Immunotherapy in Immune‐Suppressive Cholangiocarcinoma},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202207668}
}
EUVIMED